| Literature DB >> 34188341 |
Xiaobin Dong1, Luyao Liu1, Yunping Tu1, Jing Zhang1, Guijun Miao1, Lulu Zhang1, Shengxiang Ge2, Ningshao Xia2, Duli Yu1,3, Xianbo Qiu1.
Abstract
PCR has beeene">n widely used in differeene">nt fields inEntities:
Keywords: COVID-19; Microfluidics; Pathogen Detection; Point-of-Care Testing (POCT); Rapid PCR; Thermal Cycling
Year: 2021 PMID: 34188341 PMCID: PMC8223007 DOI: 10.1016/j.trac.2021.116377
Source DB: PubMed Journal: Trends Analyt Chem ISSN: 0165-9936 Impact factor: 12.296
Fig. 1Procedure of the detection to SARS-CoV-2 with PCR.
Fig. 2A brief summarization of typical PCR reactors.
Fig. 3(A) Continuous-flow chip including PCR and electrophoresis [29]. (B) Instrument-free CPCR [36]. (C) Rotary PCR system [39]. (D) Non-contact photonic heating to the PCR reagent itself [47]. (E) Non-contact photonic heating to AuBPs mixed with PCR reagent [48]. (F) Microwave heating to PCR reagent [49].
Fig. 4Representative commercialized devices for rapid detection to SARS-CoV-2 viruses.
The system ratio γ and the corresponding limit of detection of different devices.
| Category | Characteristics | Thermal cycling time (min) | Reactor size (μL) | System ratio γ (min/μL) | Limit of detection | Reference |
|---|---|---|---|---|---|---|
| γ ≥ 5.88 | Low compatibility with clinical diagnosis of infectious diseases | ~ 2.16 | ~ 0.02 | 108 | 75 copies/single well | [ |
| 6 | 0.1 | 60 | NA | [ | ||
| 26.5 | 1.3 | 20.38 | 0.1 ng/μL | [ | ||
| 25.5 | 1 | 25.5 | 12 ag (~2 copy number) | [ | ||
| 50 | 8.5 | 5.88 | 80 ng/μL | [ | ||
| γ < 5.88 | High compatibility with clinical diagnosis of infectious diseases | 24 | 20 | 1.2 | 1 pg | [ |
| 10 | 10 | 1 | 1 ng/μL | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 20 | 25 | 0.8 | 10 copies | [ | ||
| 7.5 | 10 | 0.75 | 1 pg/μL | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 30 | 40 | 0.75 | 1.0 | [ | ||
| 6.14 | 25 | 0.09 | 125 cfu/μL | [ | ||
| 13.8 | 50 | 0.276 | 10−3 ng/μL | [ | ||
| 20 | 6 | 3.33 | NA | [ | ||
| 30 | 10 | 3 | 108 copies/μL | [ | ||
| 76 | 25 | 3.04 | NA | [ | ||
| 50 | 20 | 2.5 | NA | [ | ||
| Commercialization | 25 | 5–30 | 0.83–5 | 200 copies/μL | [ | |
| 30 | 25–50 | 0.75 | 1112 copies/mL | [ | ||
| ≤11 (positive) | 25–50 | 0.22–1.2 | 900 copies/mL | [ | ||
| ~ 30 (positive) | 25–50 | 0.6–1.8 | 0.0200 PFU/mL | [ | ||
| ≤5 (positive) | 25–50 | 0.1–0.52 | 125 genome equivalents/mL | [ | ||
| ~ 45 | 25–50 | 0.9–1.8 | Heat-inactivated virus ATCC VR-1986HK 500 copies/mL | [ |